With promising new obesity treatments in the pipeline, 24/7 Wall St. projects huge upside for Novo Nordisk stock through 2030 ...

Novo Nordisk NVO shares have gained 5.8% in a week. The uptrend in the stock price was driven by reports of an activist hedge ...

GLP-1 drugs are revolutionizing the treatment of obesity and diabetes. Here's what to know about investing in GLP-1 stocks.

The first diabetes and obesity pill that is similar to Ozempic — but in tablet form — may actually outperform the popular ...

Founded in 1993, The Motley Fool is a financial services company dedicated to making the world smarter, happier, and richer.

EXCLUSIVE: The dialysis company believes the impact of the treatments on its own performance will be ‘neutral to positive’ ...

As more people resort to a new generation of drugs to achieve the perfect body, Leah Hardy examines the latest warnings over ...

With a backdrop of mounting industry disruption and transition, Pharm Exec’s latest listing of the top global biopharma sales ...

With many different species entering torpor for a variety of reasons, scientists are looking to their sleepy secrets for ways ...